Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase

Bone Marrow Transplantation

Volumn 42, Issue 9, 2008, Pages 597-600

  Bittencourt, H ^a   Funke, V ^b   Fogliatto, L ^c   Magalhaes S ^a   Setubal, D ^b   Paz, A ^c   Macedo, A V ^a   Ruiz, J ^b   Azambuja, A P ^b   Silla, L ^c   Clementino, N ^a   Pasquini, R ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; IMATINIB; INTERFERON; METHOTREXATE;

ADULT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 56349094230     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.218     Document Type: Article

References (18)

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, FordJM et al Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, FordJM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib comparedwith interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloidleukemia. N Engl J Med 2003; 348: 994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
5. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood 2006; 108: 1478-1484.
6. Gratwohl A, BrandR, Apperley J, Crawley C, Ruutu T, Corradini P et al Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
7. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
8. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452-459.
9. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC et al The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109 1782-1789.
10. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloidleukemia. Blood 2007; 109: 4686-4692.
11. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al. Favorable long-term follow-up results over 6 years for response, survival, andsafety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039-1043.
12. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613-620.
13. Weisser M, Ledderose G, Jochem Kolb H. Long-term follow-up of allogeneic HSCT for CML reveals signi?cant improvement in the outcome over the last decade. Ann Hematol 2007; 86: 127-132.
14. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD et al Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for BloodandMarrow Transplantation. Blood 2006; 108: 4288-4290.
15. Sanz GF, Saavedra S, Jimenez C, Senent L, Cervera J, Planelles D et al. Unrelatedd onor cord blood transplantation in adults with chronic myelogenous leukemia: Results in nine patients from a single institution. Bone Marrow Transplant 2001; 27: 693-701.
16. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456-3462.
17. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878.
18. Shah NP. Medical management of CML. Hematol Am Soc Hematol Educ Program 2007; 2007: 371-375.